Eyenovia Inc (NASDAQ:EYEN)’s share price was up 11.2% during trading on Friday . The stock traded as high as $3.84 and last traded at $3.67, approximately 100,328 shares changed hands during trading. A decline of 32% from the average daily volume of 147,575 shares. The stock had previously closed at $3.30.
Several equities analysts have recently commented on EYEN shares. Zacks Investment Research upgraded Eyenovia from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research note on Friday, August 16th. ValuEngine upgraded Eyenovia from a “hold” rating to a “buy” rating in a research note on Friday.
The stock has a market cap of $60.34 million, a PE ratio of -2.02 and a beta of 1.13. The firm has a 50 day moving average price of $3.68 and a 200 day moving average price of $4.58.
In related news, CEO Tsontcho Ianchulev bought 233,813 shares of the business’s stock in a transaction on Thursday, July 11th. The shares were bought at an average price of $2.78 per share, for a total transaction of $650,000.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Curt H. Labelle bought 17,985 shares of the business’s stock in a transaction on Thursday, July 11th. The stock was bought at an average price of $2.78 per share, for a total transaction of $49,998.30. The disclosure for this purchase can be found here. 43.10% of the stock is owned by insiders.
An institutional investor recently raised its position in Eyenovia stock. Vanguard Group Inc. raised its stake in Eyenovia Inc (NASDAQ:EYEN) by 72.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 139,748 shares of the company’s stock after purchasing an additional 58,697 shares during the period. Vanguard Group Inc. owned 0.85% of Eyenovia worth $601,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 8.90% of the stock is owned by institutional investors.
Eyenovia Company Profile (NASDAQ:EYEN)
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Read More: Return On Assets
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.